TEXAS ONCOLOGY–MCALLEN TO HOST PRESS CONFERENCE FOR OCT. 25 FUNDRAISER

Breaking News
2164

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

7th Annual Walk, Run, and Ride Promotes Breast Cancer Awareness and Rallies Survivors

What:              Texas Oncology–McAllen and City Commissioner Veronica Vela Whitacre will host a press conference on Tuesday, Oct. 14 to discuss the upcoming Walk, Run, and Ride promoting breast cancer awareness.

                        The 7th edition of the event begins at 8 a.m., on Saturday, Oct. 25 at Texas Oncology–McAllen, located at 1901South Second Street. Registration for the 5k run; 2.5 or 4.5 mile walk; or 20, 40, or 60 mile bicycle rally is now open. Proceeds from the event benefit the Texas Oncology Foundation, Comfort House, Food Bank of the RGV, Infinite Love, and Aurora House. For more information or to register, visit TXOWalkRunRide.com.

- Advertisement -

When:              Tuesday, Oct. 14 –10 a.m.

Where:            Texas Oncology–McAllen, 1901 South Second Street, McAllen, Texas, 78503 

Who:               Alvaro Restrepo, M.D., medical oncologist at Texas Oncology–McAllen, and event chairman Veronica Vela Whitacre, McAllen city commissioner. Other Walk, Run, and Ride participants

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Hispanics Must Promote Longer, Healthier Lives
Next article
Video: How do you get Ebola?

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Embolism Treatment Developed at University of Michigan receives FDA clearance 

Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated. 

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -